THUNDEROBOT
872190
Ji Yao Holding Group
300108
Hangzhou Huasu Technology
301157
Flaircomm Microelectronics, Inc.
301600
Jiusheng Electric
301082
CN Stock MarketDetailed Quotes
300841 Chengdu Kanghua Biological Products
- 52.32
- -0.48-0.91%
Market Closed Jan 7 15:00 CST
6.96BMarket Cap12.74P/E (TTM)
52.79High51.56Low14.98KlotVolume52.53Open52.80Pre Close78.10MTurnover1.24%Turnover Ratio13.66P/E (Static)132.95MShares79.0052wk High2.04P/B6.30BFloat Cap42.8152wk Low63.36Limit Up120.49MShs Float439.88Historical High42.24Limit Down2.33%Amplitude33.51Historical Low2.00Dividend TTM52.12Avg Price8.74KlotAsk3.82%Div YieldTTM100Lot Size5.54KlotBid
Chengdu Kanghua Biological Products News
Express News | Overview of A-shares Share Buyback: 36 companies disclosed their buyback progress.
Chengdu Kanghua Biological Products (300841.SZ): The phase III clinical trial approval notice for the six-valent Norovirus vaccine (Pichia pastoris) has been obtained.
Chengdu Kanghua Biological Products (300841.SZ) announced that recently, the company developed a recombinant hexavalent norovirus vaccine (Pichia pastoris...
Chengdu Kanghua Biological Products (300841.SZ): Currently, the AI Siasun Robot&Automation Business has not been developed.
Glory Network reported on December 11 that Chengdu Kanghua Biological Products (300841.SZ) stated on the investor interaction platform that the company mainly engages in the research, production, and sales of human vaccines and has not yet started its Business in Siasun Robot&Automation.
Express News | Chengdu Kanghua Biological Products: Shareholders holding more than 5% and other shareholders plan to reduce their shareholding in the company.
chengdu kanghua biological products (300841.SZ): The construction of the raw liquid workshop for ACYW135 meningococcal polysaccharide vaccine group has been completed.
On November 6, Gelunhui reported that Chengdu Kanghua Biological Products (300841.SZ) stated on the investor interaction platform that the company has completed the construction of the ACYW135 group meningococcal polysaccharide vaccine raw liquid workshop and the "Chengdu Kanghua Biological Products Vaccine Production Expansion Project", which are currently in the supplementary application stage for pharmaceutical production permits, and can be put into production after obtaining the production permit.
Kanghua Biology: Report for the third quarter of 2024
Chengdu Kanghua Biological Products (300841.SZ): net income of 0.406 billion yuan in the first three quarters, a year-on-year increase of 10.02%.
Gelonghui October 28th 丨 Chengdu Kanghua Biological Products (300841.SZ) announced its third quarter report for 2024, achieving revenue of 1.06 billion yuan in the first three quarters, a year-on-year growth of 7.10%; net income attributable to shareholders of the listed company was 0.406 billion yuan, a year-on-year growth of 10.02%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 0.413 billion yuan, a year-on-year growth of 14.52%; basic earnings per share was 3.0697 yuan.
chengdu kanghua biological products (300841.SZ): Since its launch, the company's diploid cell rabies vaccine has experienced a slight increase in average selling price.
Galunhui October 15th | chengdu kanghua biological products (300841.SZ) stated at an investor relations event that the sales price of the company's diploid cell rabies vaccine is mainly determined by the company based on production costs, product positioning, target area consumption levels, and other factors. The bidding price is determined in advance and finally confirmed through the bidding process or selection process of provincial CDCs in various regions. The average sales price of the company's diploid cell rabies vaccine has slightly increased since its listing, and currently the sales price for a single vaccine injection is around 300 RMB.
Express News | chengdu kanghua biological products: It is proposed to change the purpose of repurchasing 1.7036 million shares to "for cancellation and corresponding decrease in registered capital"
Chengdu Kanghua Biological Products (300841): Continuous advancement in technology going global, shareholding plan contributing to long-term development.
In the first half of 2024, the company achieved revenue of 0.741 billion yuan. The company's revenue in the first half of 2024 was 0.741 billion yuan, a year-on-year increase of 16.81%; net income attributable to shareholders was 0.307 billion yuan, a year-on-year increase of 23.51%.
Chengdu Kanghua Biological Products (300841.SZ) has signed a strategic cooperation agreement with Sichuan Biomedical Group and Leading Capital.
chengdu kanghua biological products (300841.SZ) announced that the company (Party B) has signed an agreement with sichuan biomedical industry group pharmaceutical industry group limited...
Express News | Chengdu Kanghua Biological Products: Signed a strategic cooperation agreement.
Express News | Chengdu Kanghua Biological Products: The ACYW135 group meningococcal polysaccharide vaccine has been exported as a product.
Kanghua Biological (300841.SZ): has repurchased 2.64% of the shares.
On September 2, Gelonghui announced that Chengdu Kanghua Biological Products (300841.SZ) has repurchased a total of 3,558,675 shares of the company through a share buyback special securities account through centralized bidding as of August 31, 2024, accounting for 2.64% of the company's current total share capital. The highest fill price was 63.26 yuan per share, and the lowest fill price was 45.97 yuan per share. The total transaction amount was 188,052,434.19 yuan (excluding transaction costs). The share buyback mentioned above complies with the company's buyback plan and relevant laws and regulations.
chengdu kanghua biological products (300841): Steady growth in human diploid rabies vaccine, employee stock ownership plan demonstrates confidence in development.
Chengdu Kanghua Biological Products released its 2024 interim report: 0.74 billion yuan in revenue in the first half of 2024, a year-on-year growth of 16.81%; net income attributable to shareholders of 0.307 billion yuan, a year-on-year growth of 23.51%; non-GAAP net income attributable to shareholders
Chengdu Kanghua Biological Products (300841): The performance in the first half of 2024 has grown steadily, and the double diploid rabies vaccine has been released on schedule.
Volume release as scheduled: On August 17, 2024, Chengdu Kanghua Biological Products disclosed the 2024 interim report, with the company achieving revenue of 0.741 billion yuan in H1 2024, a year-on-year increase of +16.81%; achieving a net income attributable to the parent of 3 billion yuan.
Chengdu Kanghua Biological Products achieved double-digit growth in revenue and net income in the first half of the year, and implemented an employee stock ownership plan to build a value community.
After Chengdu Kanghua Biological Products achieved double growth in revenue and net income in 2023, its performance in the first half of this year has once again brought good news. On August 16th, Chengdu Kanghua Biological Products released its half-year performance report. The financial report shows that in the first half of this year, Chengdu Kanghua Biological Products achieved revenue of 0.741 billion yuan, a year-on-year increase of 16.81%. The net income attributable to shareholders of listed companies was 0.307 billion yuan, a year-on-year increase of 23.51%. At the same time, the company's non-recurring net profit attributable to shareholders of listed companies and net cash flows generated from operating activities have also greatly improved. Apart from the stable sales of the core product, the human diploid vaccine,
Chengdu Kanghua Biological Products (300841): Significant growth in sales of main products in Q2 24, bullish on long-term development of employee shareholding plan.
Key points: In the first half of 2024, the company's performance steadily grew, with significant growth in sales of the main product, the human diploid rabies vaccine, in Q2 of 24, driving performance growth. The company continues to promote terminal sales of the human diploid rabies vaccine.
Chengdu Kanghua Biological Products: Half-year report for the year 2024.
Chengdu Kanghua Biological Products: Summary of Half-Year Report in 2024.
